1,2,3,4,5,6-HexabromocyclohexaneJAK2 tyrosine kinase inhibitor CAS# 1837-91-8 |
- CYT387 sulfate salt
Catalog No.:BCC1506
CAS No.:1056636-06-6
- Baricitinib phosphate
Catalog No.:BCC1401
CAS No.:1187595-84-1
- JAK2 Inhibitor V, Z3
Catalog No.:BCC1667
CAS No.:195371-52-9
- Bardoxolone methyl
Catalog No.:BCC1400
CAS No.:218600-53-4
- Ruxolitinib (INCB018424)
Catalog No.:BCC1276
CAS No.:941678-49-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1837-91-8 | SDF | Download SDF |
| PubChem ID | 74603 | Appearance | Powder |
| Formula | C6H6Br6 | M.Wt | 557.54 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | NSC 7908 | ||
| Solubility | Soluble to 10 mM in DMSO with gentle warming | ||
| Chemical Name | 1,2,3,4,5,6-hexabromocyclohexane | ||
| SMILES | C1(C(C(C(C(C1Br)Br)Br)Br)Br)Br | ||
| Standard InChIKey | QFQZKISCBJKVHI-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C6H6Br6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potently and directly inhibits JAK2 tyrosine kinase autophosphorylation, specifically inhibiting ligand-dependent JAK2 activation. A 16-hour treatment with 1 μM of compound reduces JAK2 tyrosine autophosphorylation levels to ~ 50% while 50 μM elimates nearly all JAK2 activity. Non-cytotoxic at 100 μM. |
1,2,3,4,5,6-Hexabromocyclohexane Dilution Calculator
1,2,3,4,5,6-Hexabromocyclohexane Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7936 mL | 8.968 mL | 17.9359 mL | 35.8719 mL | 44.8398 mL |
| 5 mM | 0.3587 mL | 1.7936 mL | 3.5872 mL | 7.1744 mL | 8.968 mL |
| 10 mM | 0.1794 mL | 0.8968 mL | 1.7936 mL | 3.5872 mL | 4.484 mL |
| 50 mM | 0.0359 mL | 0.1794 mL | 0.3587 mL | 0.7174 mL | 0.8968 mL |
| 100 mM | 0.0179 mL | 0.0897 mL | 0.1794 mL | 0.3587 mL | 0.4484 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Potently and directly inhibits JAK2 tyrosine kinase autophosphorylation, specifically inhibiting ligand-dependent JAK2 activation. A 16-hour treatment with 1 μM of compound reduces JAK2 tyrosine autophosphorylation levels to ~ 50% while 50 μM elimates nearly all JAK2 activity. Non-cytotoxic at 100 μM.
- Penthiopyrad
Catalog No.:BCC8072
CAS No.:183675-82-3
- CYN 154806
Catalog No.:BCC5823
CAS No.:183658-72-2
- Cleroindicin A
Catalog No.:BCC8916
CAS No.:176598-06-4
- Apicidin
Catalog No.:BCC3599
CAS No.:183506-66-3
- CPPG
Catalog No.:BCC6872
CAS No.:183364-82-1
- Erlotinib
Catalog No.:BCC1557
CAS No.:183321-74-6
- OSI-420
Catalog No.:BCC4472
CAS No.:183320-51-6
- Erlotinib Hydrochloride
Catalog No.:BCC3645
CAS No.:183319-69-9
- 5-(1-Piperazinyl)benzofuran-2-carboxamide
Catalog No.:BCC8717
CAS No.:183288-46-2
- 2-Acetoxy-3-deacetoxycaesaldekarin E
Catalog No.:BCN7476
CAS No.:18326-06-2
- AM251
Catalog No.:BCC4412
CAS No.:183232-66-8
- 1,7-Dihydroxy-2,3-methylenedioxyxanthone
Catalog No.:BCN7543
CAS No.:183210-63-1
- MRS 1220
Catalog No.:BCC6972
CAS No.:183721-15-5
- Amyloid β-Protein (1-15)
Catalog No.:BCC1003
CAS No.:183745-81-5
- Cyanidin 3-sophoroside chloride
Catalog No.:BCN2611
CAS No.:18376-31-3
- Mithramycin A
Catalog No.:BCC2470
CAS No.:18378-89-7
- Ciproxifan
Catalog No.:BCC4539
CAS No.:184025-18-1
- Ciproxifan maleate
Catalog No.:BCC4049
CAS No.:184025-19-2
- sitaxsentan
Catalog No.:BCC1951
CAS No.:184036-34-8
- Dimeric coniferyl acetate
Catalog No.:BCN1148
CAS No.:184046-40-0
- Calystegine B4
Catalog No.:BCN1881
CAS No.:184046-85-3
- Isoleojaponin
Catalog No.:BCN7442
CAS No.:1840966-49-5
- Hautriwaic acid
Catalog No.:BCN4686
CAS No.:18411-75-1
- GB 2a
Catalog No.:BCN7425
CAS No.:18412-96-9
Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation].[Pubmed:15801842]
J Med Chem. 2005 Apr 7;48(7):2526-33.
The commercially available Jak2 inhibitor, alpha-cyano-3,4-dihydroxy-N-benzylcinnamide (AG490), has been used extensively to study Jak2 kinase function. While alpha-cyano-3,4-dihydroxy-N-benzylcinnamide is a potent Jak2 inhibitor, it can inhibit a number of other kinase signaling pathways as well. To circumvent this problem, we sought to identify novel small molecule inhibitors of Jak2 tyrosine kinase activity. For this, we constructed a homology model of the Jak2 kinase domain and identified solvent accessible pockets on the surface of the structure. Using the DOCK program, we tested 6451 compounds of known chemical structure in silico for their ability to interact with a pocket positioned adjacent to the activation loop. We attained the top seven scoring compounds from the National Cancer Institute and tested their ability to inhibit Jak2 autophosphorylation in vitro. Using Western blot analysis, we found that one of the compounds, 1,2,3,4,5,6-Hexabromocyclohexane, was able to potently, and directly, inhibit Jak2 autophosphorylation. Characterization of this compound revealed that it inhibits Jak2 tyrosine autophosphorylation in both a time- and concentration-dependent manner. It greatly reduced growth hormone-mediated Jak2 autophosphorylation but did not block autophosphorylation of the epidermal growth factor receptor. Furthermore, doses as high as 100 muM were not toxic to cells as measured by their ability to exclude propidium iodide. As such, we believe that this compound could serve as a lead compound for a new generation of Jak2 inhibitors and, perhaps, be useful in elucidating the mechanisms of Jak2 kinase function.
